ArticleVascular pharmacology2015
Optogenetic approach for functional assays of the cardiovascular system by light activation of the vascular smooth muscle.
Article in Vascular pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- Cardiac optogenetics: a decade of enlightenment.Nature reviews. Cardiology · 2021Review
- Novel Optics-Based Approaches for Cardiac Electrophysiology: A Review.Frontiers in physiology · 2021Review
- A Light Wand to Untangle the Myocardial Cell Network.Methods and protocols · 2019Review
- Defining the ionic mechanisms of optogenetic control of vascular tone by channelrhodopsin-2.British journal of pharmacology · 2018Article
- Fiber bundle-based integrated platform for wide-field fluorescence imaging and patterned optical stimulation for modulation of vasoconstriction in the deep brain of a living animal.Biomedical optics express · 2017Article
- Optogenetic Modulation of Urinary Bladder Contraction for Lower Urinary Tract Dysfunction.Scientific reports · 2017Article
- Mitochondrial Redox Opto-Lipidomics Reveals Mono-Oxygenated Cardiolipins as Pro-Apoptotic Death Signals.ACS chemical biology · 2016Article
- Optogenetic intervention to the vascular endothelium.Vascular pharmacology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Cardiovascular diseases are the major challenge to modern medicine. Intervention to cardiovascular cells is crucial for treatment of the diseases. Here we report a novel intervention to vascular smooth muscle (VSM) cells by optogenetics. Channelrhodopsin in a tandem with YFP was selectively expressed in smooth muscle of transgenic mice in which YFP fluorescence was found in arterial walls of various tissues. In dissociated VSM cells from the mice blue light evoked inward currents, leading to depolarization and contraction. In isolated mesenteric arterial rings, optostimulation produced vasoconstriction that was reproducible, sustained, light intensity-dependent and comparable to popular vasoconstrictors. Blue light raised robustly coronary resistance without significant effects on heart rate and pulse pressure. Optostimulation produced renal vasoconstriction as well. The optical vasoconstriction had temporal resolutions less than 40s in these organs. These results indicate that optical vasoconstriction can be effectively produced in various organs with channelrhodopsin expression in VSM cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.